THE ROLE OF CORPORATE INTEGRITY AGREEMENTS IN THE EXPANSION OF FIDUCIARY DUTIES

Wulf A. Kaal and Elizabeth R. Malay†

I. INTRODUCTION ............................................................... 442
II. EXPANDING FIDUCIARY DUTIES ............................... 445
III. CORPORATE INTEGRITY AGREEMENTS .................. 448
    A. BACKGROUND .......................................................... 448
    B. CHARACTERISTICS ............................................... 450
    C. REACH AND SCOPE .............................................. 451
IV. THE ROLE OF CIAS IN EXPANDING FIDUCIARY DUTIES ............................................. 454
    A. CONTRACTUAL ADDENDUM TO INCREASE DUTIES .. 455
    B. DELINEATING THE ROLE OF CIAS IN FIDUCIARY DUTIES .............................................. 456
    C. LIMITATIONS ....................................................... 461
V. CONCLUSION ................................................................. 463

ABSTRACT
Academics have long debated the purpose and scope of fiduciary duties. The academic debate has mostly ignored the role of Corporate Integrity Agreements (CIAs). CIAs can blur the line between the law and aspirational governance. As a contractual arrangement, the terms of CIAs between health care companies and the government require heightened compliance duties. Unlike regular contractual arrangements, however, the enforcement of CIAs goes beyond contractual remedies. The breach of a CIA can be treated like

† Wulf A. Kaal is an Associate Professor, University of St. Thomas School of Law (Minneapolis) and wishes to thank research librarians Valerie Aggerbeck and Megan McNevin for their outstanding support. Elizabeth R. Malay holds a J.D. 2013, University of St. Thomas School of Law, is an Associate at Winthrop & Weinstine, P.A., Minneapolis, and worked in medical sales for seven years at Alcon Laboratories, Inc.
a breach of law for purposes of the duty of care.

Courts are increasingly recognizing the role of CIAs and their implications for directors’ fiduciary duties. A prominent recent decision, In re Pfizer, \(^1\) illustrates the role of CIAs in the evolution of fiduciary duties. Although the court in Pfizer did not conclude that the CIAs actually created fiduciary duties, the court opined that the CIAs “imposed affirmative obligations on Pfizer’s board that went well beyond the basic fiduciary duties required by Delaware law.” \(^2\) A broader reading of this phraseology suggests that fiduciary duties could perhaps be augmented by contractual arrangements such as CIAs. It seems possible that future courts, in following this reasoning, may interpret CIAs as expanding the basic legal duty of care.

\(^1\) In re Pfizer Inc. S’holder Derivative Litig., 722 F. Supp. 2d 453 (S.D.N.Y. 2010).

\(^2\) Id. at 461.
I. INTRODUCTION

Traditional fiduciary duty doctrine is among the most amorphous concepts in the law and leads to confusion, inconsistency, and to cases with somewhat problematic outcomes. The standard for liability is so high that it is hard for courts to find directors in violation of their fiduciary duties. Only a board’s sustained or systematic failure to exercise oversight can result in liability. Academics have debated ways to improve the fiduciary duty doctrine for decades. There is some agreement that fiduciary duties are too vague and should be better defined. Despite various nuances on side issues, the main

---

3 Claire A. Hill & Brett H. McDonnell, Disney, Good Faith, and Structural Bias, 32 J. CORP. L. 833, 850 (2007) (discussing the various Disney cases).

4 Id. at 846.

5 Lyman P.Q. Johnson & Mark A. Sides, Sarbanes-Oxley Act and Fiduciary Duties, 30 WM. MITCHELL L. REV. 1149, 1198 (2004); see also In re Caremark Int’l Inc. Derivative Litig., 698 A.2d 959, 971 (Del. Ch. 1996).

6 See, e.g., Claire A. Hill & Brett H. McDonnell, Fiduciary Duties and Emerging Jurisprudence, in RESEARCH HANDBOOK ON THE ECONOMICS OF CORPORATE LAW 133 (Claire A. Hill & Brett H. McDonnell eds., 2012) [hereinafter Fiduciary Duties]; Johnson & Sides, supra note 5, at 1194 (“[I]n corporate law, the duties are broad and usefully ill-defined—decision-makers must act with ‘loyalty’ and ‘care’ and in ‘good faith,’ but are accorded wide latitude in discharging their governance responsibilities in conformance with these standards.”); Cheryl L. Wade, Fiduciary Duty and the Public Interest, 91 B.U. L. REV. 1191, 1192 (2011) (citing TAMAR Frankel, FIDUCIARY LAW 166 (2011)) (“[W]hen the public interest conflicts with shareholder primacy and wealth-maximization goals, courts may enforce duties that fiduciaries owe shareholders rather than enforce fiduciaries’ compliance with law and regulation that protect the public interest.”); Thomas J. Moloney, Paul R. St. Lawrence III, & Angela F. Hamarich, Fiduciary Duties, Broker-Dealers and Sophisticated Clients: A Mis-Match that Could Only Be Made in Washington, 3 J. SEC. L. REG. & COMPLIANCE 336 (2010) (providing an overview of the fiduciary duty debate); Lisa M. Fairfax, Spare the Rod, Spoil the Director – Revitalizing Directors’ Fiduciary Duty through Legal Liability, 42 Hous. L. Rev. 393, 395 (2005) (“[L]egal liability represents an essential mechanism for ensuring directors’ fidelity to their fiduciary duties and for questioning reform efforts that do not include such liability.”); Margaret M. Blair, Stakeholders as Shareholders, Ownership and Control: Rethinking Corporate Governance for the Twenty-First Century, 109 Harv. L. Rev. 1150 (1996).


8 One group of scholars emphasizes the differences between the duties of corporate officers and directors. See e.g., Paul E. McGreal, Corporate Compliance Survey, 64 BUS. LAW. 253, 273 (2008) (“Some commentators, taking their cue from agency law, have suggested that an officer’s fiduciary duties should be more demanding [than a director’s].”) (citing Lyman P.Q. Johnson & Robert V. Ricca, (Not) Advising Corporate Officers About Fiduciary Duties, 42 WAKE FOREST L. continued . . .
debate focuses on whether improvements to the fiduciary duty doctrine can be attained through expansion or curtailment of the doctrine.

The academic debate on options for improvement of the fiduciary duty doctrine has ignored the possible role of Corporate Integrity Agreements (CIAs). CIAs are administratively-enforced compliance programs funded by health care companies but enforced by the government. In other words, they are contracts between health care companies and the federal government and can involve costly mandatory compliance measures and penalties. Because the directors contractually agree to increase compliance by way of an open door policy with the government, CIAs can substantially increase the risk of liability for companies whose directors do not act in accordance


10 Ribstein, supra note 7, at 900 (arguing for a more precise definition and more limited application of fiduciary duties).


12 A board that executes a CIA agrees to increased governmental scrutiny, including, but not limited to, granting permission for government site visits during the term of the CIA. Corporate Integrity Agreement FAQ, U.S. DEPT. HEALTH AND HUMAN SERVS. OFFICE OF INSPECTOR GEN., https://oig.hhs.gov/faqs/corporate-integrity-agreements-faq.asp (last visited Aug. 1, 2013) [hereinafter Corporate Integrity Agreement FAQ] ("[T]he purpose of a site visit is] to verify the entity’s compliance with the terms of its Corporate Integrity Agreement and to provide OIG with an opportunity to observe an entity’s compliance program in practice. The first-hand observations obtained while on site provide the OIG with a more accurate and comprehensive assessment of an entity’s compliance program. The site visit also offers the entity the unique, one-on-one opportunity to educate us regarding the entity’s operations. OIG has also found that site visits help foster more effective communication between the entity and the OIG.").
with their fiduciary responsibilities. While CIAs are outside the traditional legal framework that formally defines fiduciary duties, they fit into the penumbra of extra-legal forces that help to clarify the expectations for directors.

The contractual obligations in CIAs can enhance directors’ fiduciary duties, expanding the duty of care for directors of health care corporations beyond the legal standard under Caremark and Ritter. The duties imposed in a CIA can include, among others: the passing of specific resolutions; appointment of a chief compliance officer (CCO); agreement that the CCO will increase the frequency of reports to the board; board certification of compliance with the CIA; reporting of compliance issues to the relevant authorities; and annual reviews through an independent review organization.

Courts are increasingly recognizing the role of CIAs and their implications for directors’ fiduciary duties. A prominent recent decision, In re Pfizer, illustrates the role of CIAs in the evolution of fiduciary duties. Although the court in Pfizer did not conclude that the CIAs actually created fiduciary duties, the court opined that the CIAs “imposed affirmative obligations on Pfizer's board that went well beyond the basic fiduciary duties required by Delaware law.” A broad reading of this phraseology suggests that fiduciary duties could perhaps be augmented by contractual arrangements such as CIAs. Should other courts follow this reasoning, fiduciary duties—and more specifically directors’ basic legal duty of care—could over time expand in the CIA context.

This article includes five parts. Part II introduces the academic debate on the scope and expansion of fiduciary duties. Part III explores the main characteristics of CIAs, their reach and scope, and common denominators in executed CIAs. Part IV outlines the role of CIAs in expanding the law of fiduciary duties both as a contractual addendum and as a hybrid form of aspirational corporate governance.

13 See Optimal Penumbra, supra note 7, at 334.
17 See supra Part IV.2.
19 Id.
The authors delineate the role of CIAs in fiduciary duties by discussing relevant case law. After exploring the benefits of CIAs for the expansion of fiduciary duties, the authors outline possible limitations. Part V concludes the article.

II. EXPANDING FIDUCIARY DUTIES

The law of fiduciary duties has evolved as a result of both judicial decisions (traditional legal holdings as well as non-adjudicatory writings) and traditional equity and standards-based approaches to governance duties. Traditionally, only two fiduciary duties existed, the duties of loyalty and care. But, fiduciary duty law has evolved in the past few decades and fiduciary duties have expanded. Today, courts recognize intermediate standards, particularly the duty of good faith, making directors responsible for a triad of fiduciary duties. In addition to judicial decisions, the recent financial crises and their legislative fallout have played a role in changing the law of fiduciary duties. The Sarbanes-Oxley Act and the Dodd-Frank Act have influenced and shaped fiduciary duties but have not necessarily improved and clarified them.

20 Johnson & Sides, supra note 5, at 1151.
22 Id.; see also Optimal Penumbra, supra note 7, at 347, 353 (claiming that despite the evolution of fiduciary duties, the changes as of yet are incomplete and of disputable value, and arguing that because market forces alone cannot create an optimal director mind-set, and courts alone cannot micro-manage businesses, fiduciary duty law can and should be supplemented by extra legal forces).
23 Optimal Penumbra, supra note 7, at 338; see also Hill & McDonnell, supra note 3, at 834, 845 (citing In re Walt Disney Co. Derivative Litig., 906 A.2d 27, 66-67 (Del. 2006)).
24 Hill & McDonnell, supra note 3, at 848.
25 Johnson & Sides, supra note 5, at 1199. Johnson and Sides point out that, rather than assessing whether directors followed specific rules, judges review the manner in which directors acted. This “process” approach allows a “tailored” response to breach of fiduciary duty claims, resulting in incremental changes to fiduciary duty norms over time. Johnson & Sides, supra note 5, at 1194. Because of this “process” approach, Johnson and Sides argue that laws such as Sarbanes-Oxley are incapable of providing a comprehensive, clearly-defined approach to proper governance – fiduciary duties are much more nuanced and norm-driven than the duties required by such statutes. Johnson & Sides, supra note 5. Johnson and Sides agree that federal statutes can breathe new meaning into our understanding of proper oversight or reasonable care. Johnson & Sides, supra note 5, at 1199. For example, the duty of due care requires directors to monitor the corporation and act with appropriate oversight. Johnson & Sides, supra note 5, at 1198. One often overlooked issue is Chancellor Allen’s admonition in Caremark that directors have continued . . .
The academic debate on the scope and reach of fiduciary duties has endured for more than three decades. There is some consensus that fiduciary duties are too vague and should be better defined. A minority of scholars prefer a limited application of fiduciary duties, citing as a particular concern the expansion of fiduciary duties via federal law. To avoid confusion and inconsistency in the law of fiduciary duties, these scholars conceptualize fiduciary duties as a type of contract and a duty of unselfishness. This narrower definition of fiduciary duties is rooted in the concept of entrustment; when the

an “obligation to be reasonably informed,” that they must “exercise reasonable oversight,” and that directors must “assure a reasonable information and reporting system” exists. Johnson & Sides, supra note 5 (citing In Re Caremark Int’l Inc. Derivative Litig., 698 A.2d 959, 970-71 (Del. Ch. 1996)). What this means is that directors have an obligation to be “reasonably informed,” and what that obligation means will shift as the legislature passes federal laws setting new norms. Johnson & Sides, supra note 5. Further, part of due care requires directors to ensure their corporation’s compliance with various regulatory schemes. Johnson & Sides, supra note 5, at 1199. This duty will also shift as more laws are passed. Johnson & Sides, supra note 5. Johnson and Sides, while arguing that fiduciary duties are not federalized, acknowledge the impact that federal laws have on governance responsibilities, even though the responsibilities are still broad and open to interpretation.

See, e.g., Ribstein, supra note 7, at 899; Optimal Penumbra, supra note 7, at 336; Johnson & Sides, supra note 5, at 1194.

Ribstein, supra note 7, at 900 (arguing for a more precise definition and more limited application of fiduciary duties).

See Roberta Romano, The Sarbanes-Oxley Act and the Making of Quack Corporate Governance, 114 YALE L.J. 1523, 1529 (2005) [hereinafter Quack Corporate Governance]; Stephen M. Bainbridge, Dodd-Frank: Quack Corporate Governance Round II, 95 MINN. L. REV. 1779 (2011); Roberta Romano, Answering the Wrong Question: The Tenuous Case for Mandatory Corporate Laws, 89 COLUM. L. REV. 1779, 1785 (1989) [hereinafter Answering the Wrong Question] (arguing that corporate governance laws should not be mandatory even before SOX was passed).

Ribstein, supra note 7, at 902.

Ribstein, supra note 7, at 899-900 (arguing that a broader view of fiduciary duties has significant limitations and that the strictness of the duty of unselfishness requires a limited scope). In Meinhard v. Salmon, Justice Cardozo famously described fiduciary duties: “Joint adventurers, like copartners, owe to one another, while the enterprise continues, the duty of the finest loyalty. . . . A trustee is held to something stricter than the morals of the market place. Not honesty alone, but the punctilio of an honor the most sensitive, is then the standard of behavior.” Meinhard v. Salmon, 164 N.E. 545, 546 (N.Y. 1928). Ribstein found such a strict duty to be “only rarely appropriate in a competitive marketplace,” so therefore only required in relationships where power was entrusted to a non-owner. Ribstein, supra note 7, at 903. Instead of a broad, vague approach to fiduciary duties, Ribstein believed parties should be able to contractually adjust the duties promised and be held to a simple duty of unselfishness in relationships where there is an entrustment of power. Ribstein, supra note 7, at 907.
control of an organization is separated from the ownership of that organization, the fiduciary duty owed by the controllers protects the owners.\textsuperscript{31} In these relationships, it would be costly or impracticable for the owner to fully monitor the controller.\textsuperscript{32} Hence, fiduciary duties exist to compensate for owners’ inability to fully monitor the controllers.\textsuperscript{33}

A substantial part of the literature supports the expansion of fiduciary duties.\textsuperscript{34} The leading argument for the expansion of fiduciary duties is that the traditional fiduciary duty doctrine is inconsistent and can result in cases with problematic outcomes.\textsuperscript{35} An increasing number of scholars argue that extra-legal forces can further shape and expand corporate law.\textsuperscript{36} The law alone may not always require corporate directors to fulfill their fiduciary duty to shareholders, but extra-legal forces can help fill the gaps.\textsuperscript{37} Because state fiduciary duty law is permissive rather than regulatory, fiduciary standards can develop from non-legislative sources.\textsuperscript{38} The overall umbrella of fiduciary responsibilities is arguably non-binding, more akin to corporate ‘best practices,’ and aspirational in nature, making extra-legal forces a legitimate source that can help shape fiduciary duties.\textsuperscript{39} Extra-legal sources include, among others, the advice given by a corporation’s law firm, judicial pronouncements made outside the traditional legal opinion, and influential academic views in today’s corporate governance scholarship.\textsuperscript{40} These extra-legal forces can create norms that help guide directors.\textsuperscript{41}
III. CORPORATE INTEGRITY AGREEMENTS

Corporate integrity agreements can have an impact on fiduciary duties and corporate governance. CIAs are administratively-enforced compliance programs funded by health care companies but enforced by the government. CIAs can enhance directors’ fiduciary duties if directors contractually agree to increase compliance for the companies they manage. Through this mechanism, CIAs increase the stakes for companies whose directors do not act in accordance with their fiduciary responsibilities. Enforcement of CIAs can result in costly mandatory compliance measures and penalties.42

The enhanced duties that can be imposed on boards include: appointment of a chief compliance officer (CCO); agreement that the CCO will increase the frequency of reports to the board; board certification of compliance with the CIA; reporting of compliance issues to the relevant authorities; and annual reviews through an independent review organization. CIAs are not part of the legal framework that defines fiduciary duties. However, CIAs are part of the penumbra of extra-legal forces43 that can expand and help clarify the scope of fiduciary duties.

A. Background

CIAs are a relatively new phenomenon. Beginning in the 1990s, the Department of Health and Human Services Office of the Inspector General (OIG) started using CIAs to resolve False Claims Act investigations.44 CIAs have evolved from an informal set of self-disclosure programs into a formalized process,45 requiring the OIG to negotiate CIAs with health care providers and other entities as part of settlements in the context of health care program investigations under false claims statutes.46 In exchange for providers’ agreement to be bound by the CIA’s substantive provisions, the OIG does not exclude the providers from participation in federal health care programs, including Medicare and Medicaid.47 In effect, the OIG uses providers’ participation in federal health care programs, and the revenues generated through participation, as leverage to negotiate substantive

42 Luce, supra note 11.
43 See Optimal Penumbra, supra note 7, at 334.
45 Id. (discussing, specifically, the Defense Industry Initiative).
46 Corporate Integrity Agreements, supra note 16; see also McGreal, supra note 8, at 265.
47 McGreal, supra note 8, at 265.
provisions in CIAs that increase compliance with expected conduct and overall welfare.

The provisions in CIAs are diverse and depend on the specific terms of the settlement. CIAs are generally adjusted to the fact-specific requirements of the individual company and take preexisting compliance programs into account. During the term of a CIA, the company that executed the CIA with the government is required to increase compliance functions, including upgrades to the internal compliance structure, increased third-party oversight, and enhanced reporting requirements. In effect, a company that executes a CIA agrees to increased government scrutiny including OIG site visits during the term of the CIA.

Noncompliance with a CIA carries serious penalties. Upon noncompliance with the terms of a CIA, the OIG can prosecute the company or seek its exclusion from federal health care programs. The penalties under CIAs affect the respective entity and individuals who work for the entity. For instance, companies subject to supervision by the Food and Drug Administration (FDA) may not employ individuals who were dismissed for CIA violations as a

---

48 See Corporate Integrity Agreements, supra note 16 (“A comprehensive CIA typically lasts 5 years and includes requirements to: hire a compliance officer/appoint a compliance committee; develop written standards and policies; implement a comprehensive employee training program; retain an independent review organization to conduct annual reviews; establish a confidential disclosure program; restrict employment of ineligible persons; report overpayments, reportable events, and ongoing investigations/legal proceedings; and provide an implementation report and annual reports to OIG on the status of the entity’s compliance activities.”).

49 James N. Czaban, Meeting the Challenge of Increased Enforcement for Food and Drug Industry Clients, in RECENT DEVELOPMENTS IN FOOD AND DRUG LAW 113, 117 (Eddie Fournier, ed., 2012).

50 Corporate Integrity Agreement FAQ, supra note 12 (“[The purpose of a site visit is] to verify the entity’s compliance with the terms of its Corporate Integrity Agreement and to provide OIG with an opportunity to observe an entity’s compliance program in practice. The first-hand observations obtained while on site provide the OIG with a more accurate and comprehensive assessment of an entity’s compliance program. The site visit also offers the entity the unique, one-on-one opportunity to educate us regarding the entity's operations. OIG has also found that site visits help foster more effective communication between the entity and the OIG.”).

“Covered Person.” The careers of directors and officers in the pharmaceutical industry who were prosecuted in the context of CIA violations can be severely affected.

CIAs can also facilitate the pursuit of increased sanctions against noncompliant companies. Certification requirements in CIAs, which require directors and officers to certify compliance with the CIA’s provisions, can lower procedural and enforcement hurdles. The number of individuals who are required to provide certifications under CIAs has dramatically increased in the past few years and the certification requirements go well beyond the certification requirements for the CCO. With the increased number of individuals certifying compliance with CIA provisions, the potential for false certifications and corresponding liability intensifies.

B. Characteristics

CIAs have several core characteristics that distinguish them from other contractual arrangements between companies and the government. CIAs often become the standard for expected conduct in a civil or criminal trial. CIA certification requirements can be a powerful tool for prosecutors if the government finds that the certifications misstate the corporation’s true compliance. Once a


53 Czaban, supra note 49, at 114.


55 Id. at 172.

56 Id. at 162 (“There is potential for criminal liability under 18 U.S.C. § 1001, making a material false statement to the United States, if the false certifications are made knowingly. There is also potential for False Claims Act liability for false certifications.”); see also Thomas Beimers, Caught by the CIA: Corporate Integrity Agreement Violation is Grounds for False Claims Act Liability, BEYOND HEALTHCARE REFORM (Mar. 7, 2012), http://beyondhealthcareform.com/caught-by-the-cia-corporate-integrity-agreement-violation-is-grounds-for-false-claims-act-liability/ (demonstrating that the 11th Circuit found that false certifications made as part of CIA obligations could form the basis for False Claims Act liability, and discussing U.S. ex rel. Matheny v. Medco Health Solutions, 671 F.3d 1217, 1224 (11th Cir. 2012)).


58 McDermott & Callender, supra note 54, at 162.
CIA has been executed, it is much easier for the government to reopen a case than to pursue a new one. The OIG’s increased scrutiny, the potential for crippling penalties, and the ease of further prosecution can have a substantial impact on the knowledge, monitoring, and management of boards of companies that operate under a CIA.

A CIA increases the stakes for directors choosing to eschew their governance responsibilities. A company operating under a CIA is essentially on parole. CIAs give the government direct access to a health care corporation, facilitating the detection of compliance issues. A corporation that executed a CIA often gives the OIG permission to inspect the company’s compliance documents and conduct on-site inspections to assess its compliance with the CIA. Should the government find problems upon inspection, it can increase the penalties beyond the CIA’s substantive provisions. These penalties include criminal prosecution, fines, additional CIAs, and exclusion from federally funded health care programs. The $2.3 billion Pfizer settlement in 2009 illustrates how significant possible ramifications can be for companies that engage in illegal activities after executing a CIA.

C. Reach and Scope

By imposing stringent and detailed compliance requirements, CIAs can take an active role in the day-to-day compliance functions of corporations. CIAs affect these day-to-day compliance operations by increasing the role of the Chief Compliance Officer (CCO). Should a regulated entity not have a CCO, a CIA typically mandates the appointment of a CCO. The CCO is responsible for implementing

---

59 Czaban, supra note 49, at 3.
60 Czaban, supra note 49, at 3.
61 See Corporate Integrity Agreement FAQ, supra note 12.
63 See Luce, supra note 11.
66 See, e.g., Pfizer CIA, supra note 52, at 4 (“Prior to the Effective Date, Pfizer continued . . .”
the CIA and must generally report directly to the Chief Executive Officer (CEO), not to the General Counsel or Chief Financial Officer (CFO).  CCOs under CIAs usually have direct access to the boards of directors. CIAs typically require companies to create or maintain a compliance committee that supports the CCOs in fulfilling the additional obligations and duties imposed by the CIA. The compliance committee is usually chaired by the CCO.

CIAs can include specific provisions prescribing the conduct of the boards of directors. For instance, CIAs can mandate the number of board meetings dedicated to the review of the company’s compliance program. CIAs may even require boards to adopt specific resolutions to certify the company’s compliance with the CIA and appointed a Chief Compliance Officer and Pfizer shall maintain a Chief Compliance Officer during the term of the CIA. The Chief Compliance Officer shall be responsible for developing the requirements set forth in this CIA and with Federal health care program requirements and FDA requirements.”).

67 Pfizer CIA, supra note 52 (“The Chief Compliance Officer shall be a member of senior management of Pfizer, . . . shall make periodic (at least quarterly) reports regarding compliance matters directly to the [Audit Committee], and shall be authorized to report on such matters to the Audit Committee at any time . . .. The Chief Compliance Officer shall be responsible for monitoring the day-to-day compliance activities engaged in by Pfizer as well as for any reporting obligations created under this CIA.”).


69 See, e.g., Allergan CIA, supra note 62, at 5.


71 See, e.g., Allergan CIA, supra note 62, at 6 (“The Board shall meet at least quarterly to review and oversee Allergan’s Compliance Program, including but not limited to evaluating its effectiveness and receiving updates about the activities of the Chief Compliance Officer and other compliance personnel.”).
increase reporting obligations. In effect, these provisions allow the government to contractually determine how and when a board will interact. The certification requirements can lead directors to require more detailed reports from the corporate officers and take a greater role in overseeing the company’s compliance with both the CIA and federal regulations.

In addition to increasing board obligations and duties of the CCO, CIAs can require a number of other compliance measures. Companies operating under a CIA may be required to develop and implement a written code of conduct, often used to define and explain the role of the CCO. A code of conduct implemented under a CIA may merely require the company’s full compliance with federal, state, and local laws, but it can also demand compliance with FDA requirements, or require compliance with voluntary codes. Codes of conduct also list the consequences of noncompliance with the company’s policies and procedures, the federal health care program, or FDA requirements. Codes of conduct should encourage disclosure of compliance issues and protect whistle blowers from retaliation by maintaining the anonymity of disclosures.

Other CIA provisions require companies to self-report compliance issues to the government, notify the government of communications with the FDA, establish a field force monitoring program, monitor

---

72 See, e.g., AstraZeneca CIA, supra note 70, at 6-7 (“[This resolution] shall be signed by each individual member of the Board or the Committee, summarizing its review and oversight of matters relating to AstraZeneca’s compliance with Federal health care program requirements, FDA requirements, and the obligations of this CIA. . . . The CIA goes on set forth the required minimum language to be used in this resolution:] ‘The Board of Directors [or a Committee of the Board] has made a reasonable inquiry into the operations of AstraZeneca LP and AstraZeneca Pharmaceuticals LP’s Compliance Program for the period _____, including but not limited to evaluating its effectiveness and receiving updates about the activities of its U.S. Compliance Officer and other compliance personnel. Based on its inquiry, the Board [or the Committee] has concluded that, to the best of its knowledge, AstraZeneca LP and AstraZeneca Pharmaceuticals LP have implemented an effective U.S. Compliance Program to meet Federal health care program requirements, FDA requirements, and the obligations of the Corporate Integrity Agreement.’ If the Board cannot certify such a conclusion in the required resolution, it must set forth the reasons why it is unable to do so and the steps it is taking to ensure compliance with the CIA.”).

73 See, e.g., Medtronic CIA, supra note 68, at 6.

74 See, e.g., Pfizer CIA, supra note 52, at 7-8.

75 See, e.g., DePuy CIA, supra note 70, at 4.

76 See, e.g., Allergan CIA, supra note 62, at 8.

77 See, e.g., DePuy CIA, supra note 70, at 4.

78 DePuy CIA, supra note 70, at 5.

79 See, e.g., AstraZeneca CIA, supra note 70, at 9.
non-promotional activities, provide mandatory compliance training and education for employees, upgrade review procedures, increase disclosure programs, define ineligible persons for employment, and report physician payments. All of these additional requirements, especially the self-reporting provisions, require companies to spend additional resources and, at times, alter their day-to-day operations after signing a CIA.

IV. THE ROLE OF CIAS IN EXPANDING FIDUCIARY DUTIES

Courts differentiate between the law and aspirational corporate governance. Corporate fiduciary duties and remedies for duty violations are not aspirational goals of ideal corporate governance practices. Aspirational ideas for boards’ corporate governance practices do not define standards of liability. Although CIAs are not laws, they do go beyond aspirational governance standards. CIAs set forth concrete governance rules that expand the fiduciary duties of directors. CIAs clearly define the duties of directors to be informed, exercise oversight, and establish effective reporting systems — requiring a higher standard of care for directors operating under a CIA.

Several characteristics distinguish CIAs from both the fiduciary duties doctrine and from regular contracts. Unlike the traditional fiduciary duties doctrine, CIAs set out mandatory and clearly defined best practices for companies. Unlike private contracts, companies execute CIAs to avoid further prosecution by the government for various health care fraud charges and to avoid being excluded from Medicaid and Medicare. If the government decides a CIA is warranted, the company’s hands are tied if it wants to continue to operate within its industry.

CIAs combine elements of contractual and public enforcement. As a contractual arrangement, the terms of the CIA between the company and the government dictate heightened compliance duties for the company. Unlike regular contractual arrangements, however, the enforcement of CIAs goes beyond contractual remedies. The OIG may enforce CIAs and private rights of action may also come into play. Because of the combination of enforcement mechanisms, CIAs

---

80 AstraZeneca CIA, supra note 70, at 16-17, 22, 24, 26-27, 31, 37.
82 In re Johnson & Johnson Derivative Litig., 865 F. Supp. 2d 545, 559-60 (D.N.J. 2011).
83 Brehm v. Eisner, 746 A.2d 244, 256 (Del. 2000).
84 Id.; In re Johnson & Johnson, 865 F. Supp. 2d. at 560.
are more than contractual arrangements. Under Delaware law, CIAs may not only be enforced by the OIG, but also by the courts via a derivative suit.\(^8\)

### A. Contractual Addendum to Increase Duties

In lieu of a special hybrid category for CIAs, they are first and foremost contracts. As contracts, CIAs can create a contractual addendum to existing legal duties. To the extent that CIAs mandate specific actions in the day-to-day operations of boards of directors, CIAs can expand boards’ duties. For instance, although federal law prohibits off-label marketing of drugs and devices,\(^6\) boards are consistently held not liable for companies’ illegal marketing efforts.\(^7\) However, boards that certify compliance with a CIA are certifying that the company is properly monitoring the promotional activities of its sales teams. Through such certifications, CIAs contractually expand the applicable legal standards for boards.

CIAs can contractually expand directors’ duties beyond the Caremark standard and its progeny. Several CIA features suggest that directors are held to a higher standard after a CIA has been executed. Individual CIA provisions can put boards on notice, highlight extra care requirements in specific areas of operation, and enable the directors to increase their knowledge of the corporation’s activities and corresponding compliance requirements, making it easier to carefully and effectively monitor the organization. More specifically, because CIAs often mandate a CCO and dictate how the CCO interacts with the board, CIAs can increase boards’ knowledge and monitoring of the company’s compliance.\(^8\) If a board possesses such knowledge, it should play a bigger role in ensuring that the company meets federal and state standards. Moreover, CIAs often require boards to pass specific resolutions certifying compliance.\(^9\)

\(^8\) In re Caremark Int’l Inc. Derivative Litig., 698 A.2d 959, 960 (Del. Ch. 1996).


\(^8\) See, e.g., Pfizer CIA, supra note 52, at 44 (demonstrating that Pfizer had to submit a written Implementation Report that includes a “certification from the Chief Compliance Officer that, to the best of his/her knowledge” Pfizer is posting payment information on its website); see also AstraZeneca CIA, supra note 70, at 5 (AstraZeneca “appointed a U.S. Compliance Officer” to monitor “day-to-day compliance activities.”).

\(^9\) See, e.g., AstraZeneca CIA, supra note 70, at 6.
increasing boards’ operational knowledge (thus allowing for a more comprehensive approach to governance), CIAs also demand assurances that boards are meeting their fiduciary duties.

CIA provisions can create economic incentives that affect directors’ diligence in exercising their duties. CIAs can have harsh economic consequences for companies. CIAs provide for penalties in cases of noncompliance. Companies agree in their respective CIA to pay penalties for each day of noncompliance with the agreement. Penalties can add up to thousands of dollars per day. Additionally, most federal health law regulations provide for monetary penalties in cases of noncompliance. Because of the required self-reporting, a company operating under a CIA may be required to report violations of the False Claims Act, Sunshine, Stark, AKS, HIPAA, or other federal health laws. Adding the stipulated penalties in CIAs to the monetary penalties under federal health laws, companies that executed CIAs face significant financial ramifications.

B. Delineating the Role of CIAs in Fiduciary Duties

Caremark underscores that a lack of oversight claim “is possibly the most difficult theory in corporation law upon which a plaintiff might hope to win judgment.” Courts dismiss duty of care cases routinely at the pleading stage.

Courts, however, treat companies that executed a CIA differently.

90 AstraZeneca CIA, supra note 70, at 6.
91 See AstraZeneca CIA, supra note 70, at 52.
93 A number of recent cases illustrate that courts have not allowed breach of fiduciary duty suits to proceed when plaintiffs did not make demand upon the boards and failed to adequately plead demand futility. See King v. Baldino, 648 F. Supp. 2d 609, 610 (D. Del. 2009) (dismissing the complaint on the basis that plaintiff did not adequately plead demand futility) (quoting Stone ex rel. v. Ritter, 911 A.2d 362, 373 (Del. 2006)) (“With the benefit of hindsight, the plaintiffs’ complaint seeks to equate a bad outcome with bad faith. The lacuna in the plaintiffs’ argument is a failure to recognize that the directors’ good faith exercise of oversight responsibility may not invariably prevent employees from violating criminal laws, or from causing the corporation to incur significant financial liability, or both, as occurred in . . . this very case.”). See also Markewich v. Collins, 622 F. Supp. 2d 802 (D. Minn. 2009) (finding that the complaint did not plead sufficient facts to allow the inference that the directors operated under a “sustained or systematic failure” to exercise oversight) (quoting Desimone v. Barrows, 924 A.2d 908, 940 (Del. Ch. 2007) (“Delaware courts routinely reject the conclusory allegation that because illegal behavior occurred, internal controls must have been deficient, and the board must have known so.”)). In a pre-CIA setting, both the Baldino and the Markewich court did not allow an assumption of director wrongdoing just because improper behavior occurred.
Courts are increasingly recognizing the role of CIAs and their implications for directors’ fiduciary duties. A prominent recent decision, In re Pfizer Inc.,\textsuperscript{94} illustrates the role of CIAs in the evolution of fiduciary duties. Although the court in Pfizer did not conclude that the CIAs actually created fiduciary duties, the court opined that the CIAs “imposed affirmative obligations on Pfizer's board that went well beyond the basic fiduciary duties required by Delaware law.”\textsuperscript{95} A broader reading of this phraseology suggests that fiduciary duties could perhaps be augmented by contractual arrangements such as CIAs. Following this reasoning, it seems possible that future courts could interpret CIAs as expanding the basic legal duty of care.

In a case with fairly egregious facts, the New Jersey District Court dismissed a derivative complaint against the Johnson & Johnson (“J&J”) board for failure to plead demand.\textsuperscript{96} Plaintiffs alleged that the J&J directors breached their fiduciary duty “by permitting and fostering a culture of systematic, calculated and widespread legal violations.”\textsuperscript{97} No CIA had been executed before the alleged misconduct.\textsuperscript{98} Plaintiffs did not make a demand on the board before filing suit.\textsuperscript{99} Plaintiffs’ allegations stated that directors should have known about the company’s questionable acts because J&J received FDA warning letters, an FDA report, subpoenas from the state attorney general, qui tam complaints, a criminal plea, and a settlement agreement with the Department of Justice.\textsuperscript{100} The court looked to Brehm v. Eisner\textsuperscript{101} to analyze the case, given the “weighty allegations of corporate misconduct and director inaction.”\textsuperscript{102} The Brehm court described its case as a case concerning whether directors may be held personally liable “for lack of due care in the corporate decision-making process” – not as a case about whether the directors failed to establish and implement “ideal corporate governance practices.”\textsuperscript{103} The Brehm court stipulated: “the law of corporate fiduciary duties and

\begin{itemize}
\item \textsuperscript{94} In re Pfizer Inc. S’holder Derivative Litig., 722 F. Supp. 2d 453, 461 (S.D.N.Y. 2010).
\item \textsuperscript{95} Id. at 461.
\item \textsuperscript{96} In re Johnson & Johnson Derivative Litig., 865 F. Supp. 2d 545, 549 (D.N.J. 2011).
\item \textsuperscript{97} Id.
\item \textsuperscript{98} See id. at 550-52 (stating that these alleged violations ranged from J & J failing to recall products to J & J subsidiaries engaging in off-label marketing campaigns).
\item \textsuperscript{99} Id. at 549.
\item \textsuperscript{100} Id. at 550.
\item \textsuperscript{101} Brehm v. Eisner, 746 A.2d 244 (Del. 2000).
\item \textsuperscript{102} In re Johnson & Johnson, 865 F. Supp. 2d. at 559.
\item \textsuperscript{103} Id. (quoting Brehm, 746 A.2d at 255-56).
\end{itemize}
remedies for violation of those duties are distinct from the aspirational goals of ideal corporate governance practices,” meaning that “aspirational ideas of good corporate governance practices for boards of directors . . . are not required by the corporation law and do not define standards of liability.” The J&J court explained that it found these words appropriate when the complaint alleged that the J&J board failed to live up to aspirational ideals but failed to allege that the directors acted in bad faith in violation of their fiduciary duties. The court here differentiated between the law and aspirational corporate governance. However, when a company is operating under a CIA, the distinction between the law and aspirational governance is less clear.

The In re Pfizer Inc. derivative suit followed a number of settlement agreements between Pfizer and the Department of Justice, including a 2009 settlement of $2.3 billion, consisting of the largest criminal fine ever imposed in the United States ($1.195 billion) and the largest civil fraud settlement in history against a pharmaceutical company ($1 billion). Following settlement agreements in 2002, 2004, and 2009, Pfizer signed three separate CIAs with the OIG. Plaintiffs alleged that Pfizer’s directors breached their fiduciary duties by causing or consciously disregarding the illegal marketing activities that led in part to the staggering 2009 settlement. Plaintiffs did not issue a demand upon the board of directors. When analyzing whether demand was futile, the court noted that “many of [the] disturbing reports [of noncompliance] were received during the same time that the board was obligated by the 2002 and 2004 CIAs to pay special attention to these very problems.”

104 Id. at 559-60 (quoting Brehm, 746 A.2d at 255-56).
105 Id.
106 Id. at 560.
108 Id. at 457.
109 Id.
110 Id. at 458.
111 Id. The court explained: “As illustrated by the sheer size of the 2009 fines, the wrongdoing here alleged was not only pervasive throughout Pfizer but also was committed in the face of the board’s repeated promises to closely monitor and prevent such misconduct, as required by the 2002 and 2004 CIAs. These CIAs, which were part of larger settlements approved by the Pfizer board, imposed affirmative obligations on Pfizer’s board that went well beyond the basic fiduciary duties required by Delaware law. Among other things, these agreements obligated Pfizer’s chief Compliance Officer to report directly to the board the allegations of misconduct here at issue so that the board could deal with them directly, rather than relying on management. There is no reason to believe this reporting requirement

continued . . .
This language is significant. The court stipulated that, in the case of a company that executed a CIA, it would allow an assumption that the directors were fully informed, and thus, willing participants in the corporate malfeasance.\textsuperscript{112} For this reason, the court found that the “plaintiffs ha[d] pleaded with sufficient particularity that a majority of directors faced a substantial likelihood of personal liability because they deliberately disregarded reports of the illegal marketing practices eventually resulting in the 2009 settlement.”\textsuperscript{113} In this case, the CIAs became the court’s proof that the directors could very well have breached their fiduciary duties.

The court in In re Pfizer cited In re Abbott Laboratories Derivative Shareholders Litigation\textsuperscript{114} [hereinafter “Abbott Labs”], a case that perhaps set the stage for the In re Pfizer holding. In Abbott Labs, the Seventh Circuit reversed the dismissal of a shareholder suit for breach of fiduciary duty for failure to adequately plead demand futility.\textsuperscript{115} In their complaint, Plaintiffs alleged that Abbott directors breached their fiduciary duty when directors were aware of a six-year history of noncompliance with the FDA, yet failed to take corrective action to prevent further problems, leading to a $100 million fine – then the largest penalty ever imposed for FDA violations.\textsuperscript{116} Plaintiffs alleged directors were aware of and should have corrected the problems because Abbott entered into a Voluntary Compliance Plan with the FDA to address areas of noncompliance six years prior to the FDA filing the injunction that led to the $100 million fine.\textsuperscript{117} Plaintiffs argued that demand would have been futile because the board members knew of the continuing noncompliance with the FDA regulations.\textsuperscript{118} Furthermore, they knew that such noncompliance would lead to severe penalties because of the enhanced government oversight facilitated by Abbott’s Voluntary Compliance Program (VCP) with the FDA, yet still ignored the FDA’s repeated warnings and chose not to stop the problematic conduct.\textsuperscript{119} The Seventh Circuit agreed, holding that it was possible the Abbott directors breached their

\begin{flushright}
was not fully complied with, thus guaranteeing that each member of the board was bombarded with allegations of continuing misconduct of the very kind that the prior settlements looked to the board to prevent.”\textsuperscript{Id. at 460-61.}
\end{flushright}

\textsuperscript{112} Id. at 461-62.
\textsuperscript{113} Id. at 462.
\textsuperscript{114} In re Abbott Labs. Derivative S’holder Litig., 325 F.3d 795 (7th Cir. 2003).
\textsuperscript{115} Id. at 811.
\textsuperscript{116} Id. at 801-02.
\textsuperscript{117} Id. at 800-01.
\textsuperscript{118} Id. at 802.
\textsuperscript{119} Id.
duty.  Although the VCP was not a CIA, the Seventh Circuit used it as evidence that the directors knew of and should have stopped noncompliant activities.

To summarize, courts assume that the boards of companies that executed a CIA have more knowledge and can exercise more control and should thus act with a heightened fiduciary duty. Directors are held to a higher standard if the company executed a CIA. The courts in *In re Pfizer* and *Abbott Labs* found that Pfizer’s CIA and Abbott’s VCP increased the boards’ knowledge about compliance issues, and the directors should have increased their monitoring to prevent further violations. Neither court accepted the directors’ arguments that they did not know about the noncompliance, because executing a CIA or CIA-like agreement means directors do know, or should know, about the respective noncompliance issues.

The *Pfizer* and *Abbott Labs* decisions suggest that CIAs and VCPs can change courts’ evaluations of fiduciary duties. Courts assume that boards operating under CIAs have more knowledge and exercise more control. However, it is unclear if corporations with CIAs will be uniformly affected. In light of the *Pfizer* precedent, future courts could hold directors of corporations that executed CIAs to a higher standard and thereby expand their basic legal duty of care if the facts suggest that CIAs provided directors with more knowledge about compliance activities.

---

120 *Id.* at 809 (“Given the extensive paper trail in Abbott concerning the violations and the inferred awareness of the problems, the facts support a reasonable assumption that there was a ‘sustained and systematic failure of the board to exercise oversight,’ in this case intentional in that the directors knew of the violations of law, took no steps in an effort to prevent or remedy the situation, and that failure to take any action for such an inordinate amount of time resulted in substantial corporate losses, establishing a lack of good faith. We find that six years of noncompliance, inspections, 483s, Warning Letters, and notice in the press, all of which then resulted in the largest civil fine ever imposed by the FDA and the destruction and suspension of products which accounted for approximately $250 million in corporate assets, indicate that the directors’ decision to not act was not made in good faith and was contrary to the best interests of the company.”) (citation omitted).

121 *Id.*


123 *In re Abbott Labs.*, 325 F.3d at 809; *In re Pfizer Inc.*, 722 F. Supp. 2d at 461.

124 See Pfizer CIA, *supra* note 52, at 4-5 (demonstrating that the Pfizer CIA contains a number of requirements that seem to ensure a well-informed board. First, the CIA requires the Chief Compliance officer to report directly to the Chief Executive Officer of Pfizer and make at least quarterly reports on compliance matters to the Audit Committee of the Board. Second, the CIA requires the Audit Committee to meet at least quarterly to review Pfizer’s Compliance Program, including receiving updates on its effectiveness. And third, the CIA requires the continued...
C. Limitations

Several important conceptual and legal distinctions separate the fiduciary duties created under Delaware precedents and the contractual obligations under CIAs. CIAs have so far been predominantly used in the health care industry.\textsuperscript{125} Health care companies serve the greater good and their mission goes beyond the mere maximization of shareholder value.\textsuperscript{126} Directors acting on behalf of their corporations in the health care industry face unique challenges. Like other directors, directors in the health care industry are required to make

Audit Committee to certify that it has made reasonable inquiries into the Compliance Program and that Pfizer is meeting the obligations of the CIA. With each certification, Pfizer’s directors are promising that they are exercising proper oversight, and acting with adequate knowledge; see also In re Pfizer Inc., 722 F. Supp. 2d at 461 (“[T]here is no reason to believe this reporting requirement was not fully complied with, thus guaranteeing that each member of the board was bombarded with allegations of continuing misconduct of the very kind that the prior settlements looked to the board to prevent.”).

\textsuperscript{125} See Barnali Choudhury, Serving Two Masters: Incorporating Social Responsibility Into the Corporate Paradigm, 11 U. P.A. J. BUS. L. 631 (2009) (“[T]he purpose of the corporation shapes the normative content of corporate law and the roles and obligations of corporate managers.”).

\textsuperscript{126} The Medtronic Mission Statement illustrates the idea that a health care corporation can (and should) strive for more than just profits: “To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health, and extend life. To direct our growth in the areas of biomedical engineering where we display maximum strength and ability; to gather people and facilities that tend to augment these areas; to continuously build on these areas through education and knowledge assimilation; to avoid participation in areas where we cannot make unique and worthy contributions. To strive without reserve for the greatest possible reliability and quality in our products; to be the unsurpassed standard of comparison and to be recognized as a company of dedication, honesty, integrity, and service. To make a fair profit on current operations to meet our obligations, sustain our growth, and reach our goals. To recognize the personal worth of employees by providing an employment framework that allows personal satisfaction in work accomplished, security, advancement opportunity, and means to share in the company's success. To maintain good citizenship as a company.” Our Mission, MEDTRONIC, http://www.medtronic.com/about-medtronic/our-mission/index.htm (last visited Feb. 13, 2014). The directors are an essential part of such mission: “The corporate director . . . is a bedrock of the health care delivery system. The oversight activities provided by the director help form the corporate vision, and at the same time promote an environment of corporate responsibility that protects the mission of the corporation and the health care consumers it serves.” OFFICE OF THE INSPECTOR GEN. OF THE U.S. DEP’T HEALTH AND HUMAN SERVS. & AM. HEALTH LAWYERS ASS’N, CORPORATE RESPONSIBILITY AND CORPORATE COMPLIANCE, AM. HEALTH LAWS. ASSOC. 11, http://www.healthlawyers.org/hlresources/PJ/InfoSeries/Documents/OIG_CorpRespCorpCompliance.pdf (last visited Aug. 5, 2013).
well-informed decisions, oversee the business, and ensure that their respective corporations comply with the law. However, the unique features of health care corporations, in combination with a complex array of federal and state health care legislation, create special challenges for directors in the health care industry. Directors of health care corporations need to balance the needs of many stakeholders such as patients, physicians, taxpayers, the government, and shareholders. Even small health care companies may have a global reach and their directors’ decisions can therefore affect a broad array of constituents. Substantial government involvement and responsibility through Medicare and Medicaid may further complicate the administration of health care providers since the taxpaying public is also a stakeholder.

Given the public good or quasi-public good character of the health care industry, the application of CIAs in industries outside of health

---

127 Id. at 5 (stating that in the health care context, the duty of care arises in either the decision-making function or the oversight function. The decision-making function applies to a particular situation or a specific action. The duty of care principle in the oversight function pertains to the general activity of overseeing the day-to-day functions of the business).


130 The decisions made by health care corporations have real costs for American taxpayers. See Daniel R. Levinson, Preventing Health Care Fraud: New Tools and Approaches to Combat Old Challenges, U.S. DEP’T OF HEALTH & HUMAN SERVS. (Mar. 2, 2011), http://www.hhs.gov/ash/testify/2011/03/t20110302i.html (“For example, in August 2010, Allergan, Inc., agreed to plead guilty to misdemeanor misbranding and paid $600 million (including a $375 million criminal fine and forfeiture and a $225 million civil settlement) to resolve criminal and civil liability arising from the company’s promotion of Botox®. Our investigations found that the company illegally marketed the drug for indications that, during the relevant time periods, had not been approved as safe and effective by the Food and Drug Administration (FDA). These unapproved indications included headache, pain, spasticity and juvenile cerebral palsy. In addition, the settlement resolved allegations that Allergan misled doctors about the safety and efficacy of Botox®, instructed doctors to miscode claims to ensure payment by Government health care programs, and paid kickbacks to doctors.”).

care could be limited. Without broader application in other industries, the impact of CIAs on corporate law may be limited.

V. CONCLUSION

CIAs add an important element to the academic debate on the expansion of fiduciary duties. As a unique hybrid category, CIAs transcend the law of fiduciary duties and aspirational corporate governance. Courts are increasingly recognizing the role of CIAs and their capacity to expand directors’ fiduciary duties. A broad reading of In re Pfizer suggests that CIAs can augment fiduciary default duties. Given the characteristics of CIAs and courts’ increasing recognition of CIAs, courts may interpret CIAs and other hybrid forms, such as deferred prosecution agreements, as expanding the basic legal duty of care. More research and empirical work may be needed to explore how CIAs and other hybrid forms may change or expand directors’ obligations.